The REVAMP trial to evaluate HIV resistance testing in sub-Saharan Africa: a case study in clinical trial design in resource limited settings to optimize effectiveness and cost effectiveness estimates

References

• UNAIDS. 90-90-90: An Ambitious Treatment Target to Help end the AIDS Epidemic. Joint United Nations Programme on HIV/AIDS (UNAIDS). 2014. http://www.unaids.org/sites/default/files/media_asset/90-90-90_en_0.pdf.
   Google Scholar
• McMahon JH, Elliott JH, Bertagnolio S, Kubiak R, Jordan MR. Viral suppression after 12 months of antiretroviral therapy in low- and middle-income countries: a systematic review. Bull World Health Organ. 2013;91(5):377–385E.10.2471/BLT.12.112946
   PubMed Web of Science ®Google Scholar
• Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis. 2010;10(3):155–166.10.1016/S1473-3099(09)70328-7
   PubMed Web of Science ®Google Scholar
• World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treatment and preventing HIV infection. Recommendations for a public health approach. 2nd ed. Geneva: World Health Organization; 2016.
   Google Scholar
• Mermin J, Ekwaru JP, Were W, et al. Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial. BMJ. 2011;343:d6792.10.1136/bmj.d6792
   PubMed Web of Science ®Google Scholar
• Mills EJ, Bakanda C, Birungi J, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: A cohort analysis from Uganda. Ann Intern Med. 2011;155(4):209–216.10.7326/0003-4819-155-4-201108160-00358
   PubMed Web of Science ®Google Scholar
• Nachega JB, Parienti JJ, Uthman OA, et al. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials. Clin Infect Dis. 2014;58(9):1297–1307.10.1093/cid/ciu046
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf.2016.
   Google Scholar
• Cohen CJ, Hunt S, Sension M, et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS. 2002;16(4):579–588.10.1097/00002030-200203080-00009
   PubMed Web of Science ®Google Scholar
• Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet. 1999;353(9171):2195–2199.10.1016/S0140-6736(98)12291-2
   PubMed Web of Science ®Google Scholar
• Haubrich RH, Kemper CA, Hellmann NS, et al. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS. 2005;19(3):295–302.
   PubMed Web of Science ®Google Scholar
• Tural C, Ruiz L, Holtzer C, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS. 2002;16(2):209–218.10.1097/00002030-200201250-00010
   PubMed Web of Science ®Google Scholar
• Weinstein MC, Goldie SJ, Losina E, et al. Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann Intern Med. 2001;134(6):440–450.10.7326/0003-4819-134-6-200103200-00008
   PubMed Web of Science ®Google Scholar
• El-Khatib Z, Delong AK, Katzenstein D, et al. Drug resistance patterns and virus re-suppression among HIV-1 subtype C infected patients receiving non-nucleoside reverse transcriptase inhibitors in South Africa. J AIDS Clin Res. 2011;2(117):e1000117.
   PubMedGoogle Scholar
• Gilks CF, Walker AS, Dunn DT, et al. Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA). Antivir Ther. 2012;17(7):1363–1373.10.3851/IMP2253
   PubMed Web of Science ®Google Scholar
• Gupta RK, Goodall RL, Ranopa M, et al. High rate of HIV resuppression after viral failure on first-line antiretroviral therapy in the absence of switch to second-line therapy. Clin Infect Dis. 2014;58(7):1023–1026.10.1093/cid/cit933
   PubMed Web of Science ®Google Scholar
• Hoffmann CJ, Charalambous S, Sim J, et al. Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin Infect Dis. 2009;49(12):1928–1935.10.1086/599195
   PubMed Web of Science ®Google Scholar
• Jobanputra K, Parker LA, Azih C, et al. Factors associated with virological failure and suppression after enhanced adherence counselling, in children, adolescents and adults on antiretroviral therapy for hiv in Swaziland. PLoS One. 2015;10(2):e0116144.10.1371/journal.pone.0116144
   PubMed Web of Science ®Google Scholar
• Ciaffi L, Koulla-Shiro S, Sawadogo A, et al. Efficacy and safety of three second-line antiretroviral regimens in HIV-infected patients in Africa. AIDS. 2015;29:1473–1481.10.1097/QAD.0000000000000709
   PubMed Web of Science ®Google Scholar
• Paton NI, Kityo C, Hoppe A, et al. Assessment of second-line antiretroviral regimens for HIV therapy in Africa. N Engl J Med. 2014;371(3):234–247.10.1056/NEJMoa1311274
   PubMed Web of Science ®Google Scholar
• Cole SR, Stuart EA. Generalizing evidence from randomized clinical trials to target populations: The ACTG 320 trial. Am J Epidemiol. 2010;172(1):107–115.10.1093/aje/kwq084
   PubMed Web of Science ®Google Scholar
• Victora CG, Habicht JP, Bryce J. Evidence-based public health: moving beyond randomized trials. Am J Public Health. 2004;94(3):400–405.10.2105/AJPH.94.3.400
   PubMed Web of Science ®Google Scholar
• Hlatky MA, Owens DK, Sanders GD. Cost-effectiveness as an outcome in randomized clinical trials. Clin Trials. 2006;3(6):543–551.10.1177/1740774506073105
   PubMed Web of Science ®Google Scholar
• Levison JH, Wood R, Scott CA, et al. The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for hiv-infected patients in South Africa. Clin Infect Dis. 2013;56(4):587–597.10.1093/cid/cis887
   PubMed Web of Science ®Google Scholar
• Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices-budget impact analysis. Value Health. 2007;10(5):336–347.10.1111/j.1524-4733.2007.00187.x
   PubMed Web of Science ®Google Scholar
• Phillips A, Cambiano V, Nakagawa F, et al. Cost-effectiveness of HIV drug resistance testing to inform switching to second line antiretroviral therapy in low income settings. PLoS One. 2014;9(10):e109148.10.1371/journal.pone.0109148
   PubMed Web of Science ®Google Scholar
• Rosen S, Long L, Sanne I, Stevens WS, Fox MP. The net cost of incorporating resistance testing into HIV/AIDS treatment in South Africa: a Markov model with primary data. J Int AIDS Soc. 2011;14:24.10.1186/1758-2652-14-24
   PubMed Web of Science ®Google Scholar
• Caro JJ, Briggs AH, Siebert U, Kuntz KM, Force I-SMGRPT. Modeling good research practices–overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–1. Value Health. 2012;15(6):796–803.10.1016/j.jval.2012.06.012
   PubMed Web of Science ®Google Scholar
• Gepner AD, Korcarz CE, Aeschlimann SE, et al. Validation of a carotid intima-media thickness border detection program for use in an office setting. J Am Soc Echocardiogr. 2006;19(2):223–228.10.1016/j.echo.2005.09.006
   PubMed Web of Science ®Google Scholar
• Robberstad B, Olsen JA. The health related quality of life of people living with HIV/AIDS in sub-Saharan Africa – a literature review and focus group study. Cost Eff Resour Allo. 2010;8:5.10.1186/1478-7547-8-5
   PubMedGoogle Scholar
• Jelsma J, MacLean E, Hughes J, Tinise X, Darder M. An investigation into the health-related quality of life of individuals living with HIV who are receiving HAART. AIDS Care. 2005;17(5):579–588.10.1080/09540120412331319714
   PubMed Web of Science ®Google Scholar
• Hughes J, Jelsma J, Maclean E, Darder M, Tinise X. The health-related quality of life of people living with HIV/AIDS. Disabil Rehabil. 2004;26(6):371–376.10.1080/09638280410001662932
   PubMed Web of Science ®Google Scholar
• Louwagie GM, Bachmann MO, Meyer K, Booysen Fle R, Fairall LR, Heunis C. Highly active antiretroviral treatment and health related quality of life in South African adults with human immunodeficiency virus infection: a cross-sectional analytical study. BMC Public Health. 2007;7:682.10.1186/1471-2458-7-244
   Web of Science ®Google Scholar
• Holtgrave DR, Pinkerton SD. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immune Defic Syndr Human Retrovirol. 1997;16(1):54–62.10.1097/00042560-199709010-00009
   PubMedGoogle Scholar
• Luz PM, Morris BL, Grinsztejn B, et al. Cost-effectiveness of genotype testing for primary resistance in Brazil. J Acquir Immune Defic Syndr. 2015;68(2):152–161.10.1097/QAI.0000000000000426
   PubMed Web of Science ®Google Scholar
• Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126(12):946–954.10.7326/0003-4819-126-12-199706150-00003
   PubMed Web of Science ®Google Scholar
• Schackman BR, Goldie SJ, Freedberg KA, Losina E, Brazier J, Weinstein MC. Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Med Decis Making. 2002;22(1):27–38.10.1177/0272989X0202200103
   PubMed Web of Science ®Google Scholar
• Wood AM, White IR, Thompson SG. Are missing outcome data adequately handled? A review of published randomized controlled trials in major medical journals. Clin Trials. 2004;1(4):368–376.10.1191/1740774504cn032oa
   PubMedGoogle Scholar
• Little RJ, D’Agostino R, Cohen ML, et al. The prevention and treatment of missing data in clinical trials. N Engl J Med. 2012;367(14):1355–1360.10.1056/NEJMsr1203730
   PubMed Web of Science ®Google Scholar
• Gabillard D, Lewden C, Ndoye I, et al. Mortality, AIDS-morbidity, and loss to follow-up by current CD4 cell count among HIV-1-infected adults receiving antiretroviral therapy in Africa and Asia: data from the ANRS 12222 collaboration. J Acquir Immune Defic Syndr. 2013;62(5):555–561.10.1097/QAI.0b013e3182821821
   PubMed Web of Science ®Google Scholar
• Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med. 2011;8(7):e1001056.10.1371/journal.pmed.1001056
   PubMed Web of Science ®Google Scholar
• Geng EH, Bangsberg DR, Musinguzi N, et al. Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. J Acquir Immune Defic Syndr. 2010;53(3):405–411.10.1097/QAI.0b013e3181b843f0
   PubMed Web of Science ®Google Scholar
• Geng EH, Emenyonu N, Bwana MB, Glidden DV, Martin JN. Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa. JAMA. 2008;300(5):506–507.10.1001/jama.300.5.506
   PubMed Web of Science ®Google Scholar
• Foulkes MA, Grady C, Spong CY, Bates A, Clayton JA. Clinical research enrolling pregnant women: a workshop summary. J Women’s Health. 2011;20(10):1429–1432.10.1089/jwh.2011.3118
   PubMed Web of Science ®Google Scholar
• Mastroianni A, Faden R, Federman D. Women and health research: ethical and legal issues of including women in clinical studies. Washington, DC: Institute of Medicine; 1994.
   Google Scholar
• National Consolidated Guidelines for the Prevention of Mother-to-Child Transmission of HIV (PMTCT) and the Management of HIV in Children, Adolescents and Adults. National Department of Health: South Africa; 2015. http://www.sahivsoc.org/upload/documents/ARTGuidelines15052015.pdf.
   Google Scholar